Last reviewed · How we verify

Nalfurafine HCl 5.0 µg

Acologix, Inc. · Phase 3 active Small molecule

Nalfurafine HCl 5.0 µg is a Kappa opioid receptor agonist Small molecule drug developed by Acologix, Inc.. It is currently in Phase 3 development for Chronic pruritus in patients with end-stage renal disease on hemodialysis, Pruritus associated with other chronic conditions.

Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.

Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system. Used for Chronic pruritus in patients with end-stage renal disease on hemodialysis, Pruritus associated with other chronic conditions.

At a glance

Generic nameNalfurafine HCl 5.0 µg
SponsorAcologix, Inc.
Drug classKappa opioid receptor agonist
TargetKappa opioid receptor (KOR)
ModalitySmall molecule
Therapeutic areaDermatology / Nephrology
PhasePhase 3

Mechanism of action

Nalfurafine binds to kappa opioid receptors, which are involved in the regulation of pruritus (itch). By activating these receptors, particularly in the spinal cord and brain regions responsible for itch sensation, it reduces the perception and transmission of itch signals. This mechanism makes it effective for treating chronic pruritus associated with conditions like uremia in dialysis patients and other chronic itch conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Nalfurafine HCl 5.0 µg

What is Nalfurafine HCl 5.0 µg?

Nalfurafine HCl 5.0 µg is a Kappa opioid receptor agonist drug developed by Acologix, Inc., indicated for Chronic pruritus in patients with end-stage renal disease on hemodialysis, Pruritus associated with other chronic conditions.

How does Nalfurafine HCl 5.0 µg work?

Nalfurafine is a selective kappa opioid receptor agonist that modulates itch signaling in the central and peripheral nervous system.

What is Nalfurafine HCl 5.0 µg used for?

Nalfurafine HCl 5.0 µg is indicated for Chronic pruritus in patients with end-stage renal disease on hemodialysis, Pruritus associated with other chronic conditions.

Who makes Nalfurafine HCl 5.0 µg?

Nalfurafine HCl 5.0 µg is developed by Acologix, Inc. (see full Acologix, Inc. pipeline at /company/acologix-inc).

What drug class is Nalfurafine HCl 5.0 µg in?

Nalfurafine HCl 5.0 µg belongs to the Kappa opioid receptor agonist class. See all Kappa opioid receptor agonist drugs at /class/kappa-opioid-receptor-agonist.

What development phase is Nalfurafine HCl 5.0 µg in?

Nalfurafine HCl 5.0 µg is in Phase 3.

What are the side effects of Nalfurafine HCl 5.0 µg?

Common side effects of Nalfurafine HCl 5.0 µg include Dizziness, Somnolence, Nausea, Headache, Constipation.

What does Nalfurafine HCl 5.0 µg target?

Nalfurafine HCl 5.0 µg targets Kappa opioid receptor (KOR) and is a Kappa opioid receptor agonist.

Related